• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Germany·Basic Materials·LXS.DE
Share

LANXESS Aktiengesellschaft Stocks

€ 16.54Last Updated 31.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

€ 1.65B

€ 16.54
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

26.03.2026 18:05

German chemical company Lanxess gets double upgraded by JPMorgan; shares soar

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

LANXESS Aktiengesellschaft, a prominent specialty chemicals firm, is engaged worldwide in the development, production, and sale of chemical intermediates, additives, specialized chemicals, and plastics. The company's operations are divided into four primary segments: Advanced Intermediates, Specialty Additives, Consumer Protection, and Engineering Materials. The Advanced Intermediates division supplies sophisticated industrial intermediates, fundamental and refined chemicals, organometallic compounds, and inorganic pigments, catering to industries like agrochemicals, automotive, construction, flavors and fragrances, semiconductors, photovoltaics, and color pigments. The Specialty Additives segment provides various specialized additives, including lubricants, flame retardants, plasticizers, and bromine derivatives, for applications in rubber, plastic, paint, construction, and electrical sectors. The Consumer Protection segment offers products for material preservation, disinfection, hygiene, and preservation, alongside flavors and fragrances, and precursors for the agrochemical, pharmaceutical, and specialty chemical industries. It also delivers technologies for water and liquid treatment. Finally, the Engineering Materials segment produces high-performance plastics, glass fibers, fiber composites, and urethane-based elastomers, which find use in the automotive, electrical/electronics, construction, medical, and sports and leisure fields. Founded in 1863, LANXESS has its headquarters situated in Cologne, Germany.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is neutral on EV/EBITDA, overpriced on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of LXS.DE is 16.5 and suggests 0.181% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.08.2026 16:10

After the July sell-off: Has the golden age for chipmakers come to an end?

03.08.2026 15:20

Warsh suggested that the Fed might reduce the number of meetings on interest rates

03.08.2026 14:41

Shares of a small-cap biotech company soared 107%. Its melanoma drug is close to approval.

03.08.2026 13:25

Morgan Stanley Expects Korean Stocks to Soar 44% After Their Worst Month Since 2008

03.08.2026 12:16

Concrete or a Presentation: How to Profit from Kazakhstan’s Investments in AI

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026